Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Reactivation of the silencedProceedings of the National Academy of Sciences of the United States of America · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Leonie I WeberInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0002-8352-5402
Lea E TimpenInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0003-3207-0230
Anna-Sophia Egger-HörschingerInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0002-5204-7121
Philemon SchöpfInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.
Nesin D AyhanInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0005-1028-9607
David DemmelInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0006-8373-3198
Madlen HotzeInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0001-1816-2089
Yang ZhangInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.
Mahdi MehrabiOtto Loewi Research Center, Division of Immunology, Medical University of Graz, Graz 8010, Austria.ORCID 0009-0009-9212-5946
Kane PuglisiInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.
Eduard StefanCenter for Molecular Biosciences, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0003-3650-4713
Nassim Ghaffari-Tabrizi-WizsyOtto Loewi Research Center, Division of Immunology, Medical University of Graz, Graz 8010, Austria.ORCID 0000-0001-6696-8717
José M Ramos-PittolInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0003-3753-5394
Marcel KwiatkowskiInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.
Markus HartlInstitute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0001-7447-5920
Funding
Austrian Science Fund (FWF) P33662
6 · The paper itself
Abstract
Starting from human colon cancer cells showing aberrant WNT/β-catenin/TCF signaling, hyperactivated
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Reactivation of the silenced · full record | OpenQuestion